EUVIMEDEUVIMED entdecken
Crossref

The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation

Xingyan Yu, Tao Li, Zhiyuan Shen, Hongyan Jing, Xiulong Xie, Xiaofei Zhou, Yuelei Shen, Yi Yang

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.109704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Xingyan Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Postgraduate, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, People's Republic of China; Joint Graduate School, Y…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last few years, immunotherapy has made significant progress in treating various cancers with therapeutic antibodies. However, therapeutic antibodies have been validated for inducing an unintended immune response in human and animal models, which leads to the emergence of anti-drug antibodies (ADAs) and affects their effectiveness and safety. In preclinical research, ADAs production by B cells may accelerate antibody metabolism and result in missing potential candidate molecules. Thus, it is urgent to develop preclinical models that remove only B cells without affecting the function of T and NK cells. Rearrangement of immunoglobulin heavy chain J gene fragment (Igh-J) is the first link in B cell development, and immunotherapies are currently leaning toward combination treatments with PD-1/PD-L1 antibodies, here we created humanized PD-1, PD-L1 and Igh-J knockout (hPD-1/hPD-L1, Igh-J KO) mice and validated by using the reported high immunogenicity drug M7824 (a protein designed to simultaneously block PD-L1 and TGF-β pathways, poorly anti-tumor efficacy in immunocompetent mice). Phenotypic analysis revealed that human PD-1 and PD-L1 were detectable in hPD-1/hPD-L1, Igh-J KO mice, but not mouse IgM and IgD. Igh-J KO depleted B cells while increased the percentage of other immune cell types. Meanwhile, the humanization of PD-1/PD-L1 and Igh-J KO had neither effect on the overall development, differentiation, or distribution of T cell subtypes, nor on the activation of NK and T cells, indicating that mice can be used for T and NK-related immunotherapies. Furthermore, M7824 treatment of these B cell-deficient mice inhibited tumor growth significantly, with higher M7824 analog concentrations and lower ADA-positive rates. These findings demonstrate that Igh-J KO mice are an effective and stable preclinical model for testing drugs based on T and NK cells with high immunogenicity in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsAnimalsMiceHumansProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalGene EditingT-LymphocytesDisease Models, Animal

Stichwörter der Autor:innen

Anti-drug antibodiesB cell-deficientImmunogenicityPreclinical mouse model

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Postgraduate, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, People's Republic of China; Joint Graduate School, Yangtze Delta Drug Advanced Research Institute, Nantong 226133, People'…
  • Institute of Innovative Medicine, Biocytogen Pharmaceuticals (Beijing) Co, Ltd, Beijing 102609, People's Republic of China.
  • Joint Graduate School, Yangtze Delta Drug Advanced Research Institute, Nantong 226133, People's Republic of China; Institute of Innovative Medicine, Biocytogen Pharmaceuticals (Beijing) Co, Ltd, Beijing 102609, People's…

Zitieren

APA

Yu, X., Li, T., Shen, Z., Jing, H., Xie, X., Zhou, X., Shen, Y., & Yang, Y. (2023). The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109704

Vancouver

Yu X, Li T, Shen Z, Jing H, Xie X, Zhou X, et al. The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109704

BibTeX
@article{Yu2023,
  author = {Yu, Xingyan and Li, Tao and Shen, Zhiyuan and Jing, Hongyan and Xie, Xiulong and Zhou, Xiaofei and Shen, Yuelei and Yang, Yi},
  title = {The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.109704}
}
Kostenlos starten →